Todd N. Smith serves as the president and chief executive officer at Latigo Biotherapeutics. Mr. Smith has more than 30 years of leadership experience commercializing biopharmaceutical products in the pain area and leading both public and private companies. His career spans commercial operations, business development and executive management, with a proven record of creating value for stockholders. He most recently served as CEO of Corium, a commercial-stage biopharmaceutical company focused on neuroscience, through its acquisition by Collegium Pharmaceutical in the second quarter of 2026.

Prior to Corium, Mr. Smith led several companies focused on the pain space, including appointments as CEO of Valinor Pharma, Iroko Pharmaceuticals, Zyla Life Sciences and Assertio Therapeutics. Earlier in his career, he served as chief commercial officer (CCO) and head of business development at Horizon Therapeutics PLC and CCO at Tolmar Pharmaceuticals, following commercial leadership roles at Abbott and Fenwal.

Mr. Smith currently serves on the boards of BVI Medical, Quetzal Therapeutics, Apollo Care and Artemis Pharma and he will continue to serve as a member of Latigo’s Board of Directors. He earned a B.A. in political science from Norwich University.